Price T Rowe Associates Inc Revance Therapeutics, Inc. Transaction History

Price T Rowe Associates Inc

$869 Billion
Q3 2024

A detailed history of Price T Rowe Associates Inc transactions in Revance Therapeutics, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 96,076 shares of RVNC stock, worth $246,915. This represents 0.0% of its overall portfolio holdings.

Number of Shares

96,076

Previous 94,453 1.72%

Holding current value

$246,915

Previous $243,000 105.35%

% of portfolio

0.0%

Previous 0.0%

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$2.57 - $2.57 $4,171 - $4,171	1,623 Added 1.72%	96,076 $499,000
Q2 2024 Aug 14, 2024	BUY	$2.34 - $4.73 $58,715 - $118,685	25,092 Added 36.18%	94,453 $243,000
Q1 2024 May 15, 2024	BUY	$4.65 - $9.31 $72,056 - $144,267	15,496 Added 28.77%	69,361 $342,000
Q4 2023 Feb 14, 2024	BUY	$5.81 - $11.2 $20,259 - $39,054	3,487 Added 6.92%	53,865 $474,000
Q3 2023 Nov 14, 2023	BUY	$11.47 - $25.07 $55,491 - $121,288	4,838 Added 10.62%	50,378 $578,000
Q2 2023 Aug 14, 2023	BUY	$24.7 - $37.61 $67,850 - $103,314	2,747 Added 6.42%	45,540 $1.15 Million
Q1 2023 May 15, 2023	SELL	$18.36 - $35.27 $10,501 - $20,174	-572 Reduced 1.32%	42,793 $1.38 Million
Q4 2022 Feb 14, 2023	SELL	$18.32 - $30.66 $11,175 - $18,702	-610 Reduced 1.39%	43,365 $801,000
Q3 2022 Nov 14, 2022	BUY	$14.33 - $28.47 $80,864 - $160,656	5,643 Added 14.72%	43,975 $1.19 Million
Q2 2022 Aug 15, 2022	BUY	$11.52 - $20.4 $4,930 - $8,731	428 Added 1.13%	38,332 $530,000
Q1 2022 May 16, 2022	BUY	$12.36 - $20.31 $68,610 - $112,740	5,551 Added 17.16%	37,904 $739,000
Q4 2021 Feb 14, 2022	BUY	$12.46 - $27.87 $94,795 - $212,034	7,608 Added 30.75%	32,353 $528,000
Q3 2021 Nov 15, 2021	BUY	$25.78 - $33.21 $5,156 - $6,642	200 Added 0.81%	24,745 $689,000
Q2 2021 Aug 16, 2021	BUY	$26.8 - $31.84 $61,720 - $73,327	2,303 Added 10.35%	24,545 $728,000
Q1 2021 May 17, 2021	SELL	$24.03 - $29.97 $165,903 - $206,912	-6,904 Reduced 23.69%	22,242 $622,000
Q4 2020 Feb 16, 2021	BUY	$23.41 - $28.34 $682,307 - $825,997	29,146 New	29,146 $826,000

Others Institutions Holding RVNC

# of Institutions

233

Shares Held

82.1M

Call Options Held

680K

Put Options Held

896K

View Full List

About Revance Therapeutics, Inc.

Ticker RVNC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 82,305,696
Market Cap $212M
Description
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...

More about RVNC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

News

Stay updated on Price T Rowe Associates Inc with notifications on news.

Account

Price T Rowe Associates Inc Revance Therapeutics, Inc. Transaction History